Please select the option that best describes you:
What would you choose as second-line therapy in patients with ER/PR-positive, HER2-negative metastatic breast cancer progressing on first-line CDK 4/6 inhibitor/AI combination?
Assume good compliance with oral therapy, equivalent access to either agent, no contraindictions to either therapy, and absence of any visceral crisis, how would you choose between fulvestrant and everolimus/exemestane?
Answer from: Medical Oncologist at Academic Institution
While we don't have direct comparative data, my own preference is fulvestrant both because in treatment-naive patients it appears better than NSAI (20% improvement in PFS in FALCON), and because the toxicity profile favors fulvestrant over everolimus/exemestane.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Combination fulvestrant/everolimus is feasible in second line-see link. The dose we used was loading dose, so conceivably high dose fulvestrant is more effective. The problem with everolimus is of course toxicity, which can be problematic, and we don't know the benefit after AI/CDK4/6 combo, only af...
Answer from: Medical Oncologist at Academic Institution
Currently, there is no data upon which to base endocrine therapy decisions after disease progression on a CDK4/6 inhibitor. I would consider either fulvestrant or a combination with everolimus (Exemestane or fulvestrant) and base the decision on factors such as desire for an all oral regimen, ...